Wave Life Sciences Ltd. — Director's Dealing 2018

Jan 26, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2018-01-23

Reporting Person: Vargeese Chandra (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-01-23	Ordinary Shares	M	2000	$2.48	Acquired	11800	Direct
2018-01-23	Ordinary Shares	S	2000	$40.00	Disposed	9800	Direct
2018-01-23	Ordinary Shares	A	17500	$0.00	Acquired	27300	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-23	Share Option (right to buy)	$2.48	M	2000	Disposed	2025-03-10	Ordinary Shares (2000)	Direct
2018-01-23	Share Option (right to buy)	$40.05	A	35000	Acquired	2028-01-23	Ordinary Shares (35000)	Direct

Footnotes

F1: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.

F2: The incentive share option initially represented a right to purchase a total of 158,042 ordinary shares, 25% of which became exercisable on August 1, 2015, and the remaining shares vest in 36 equal monthly installments thereafter.

F3: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2019, through February 15, 2022.

F4: The option vests as to 25% of the shares on February 15, 2019 and vests as to an additional 6.25% of the shares quarterly thereafter until February 15, 2022.